Sep 17, 2018   SOURCE: PR NewsWire

Global Microbiome Therapeutics & Diagnostics Market 2018-2023 - Human Therapeutic and Diagnostic Pipeline Analysis

DUBLIN, Sept. 17, 2018 /PRNewswire/ --

The "Global Microbiome Therapeutics & Diagnostics Market Analysis & Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

The global microbiome therapeutic and diagnostic market is worth $1.13 billion in 2018 and will grow at a CAGR of 19.03% over five years to $2.7 billion in 2023.

This report provides a comprehensive overview of the size of the microbiome therapeutic and diagnostic market, segmentation of the market (Gastrointestinal, Metabolic, Cancer, Neurological, Autoimmune, Skin), key players and the potential of therapies that are in clinical trials.

The majority of the market will be dominated by microbiome based therapeutics, with an estimate of 90%, compared to 10% in microbiome diagnostics.

This report describes the evolution of such a prospective market in eight chapters supported by over 82 tables and figures in 165 pages.

Key Points Covered:

    --  An overview of the human microbiome space that includes how the market
        is sub-divided into therapeutics (prebiotics, probiotics, fecal
        microbiota transplantation, small molecules) and diagnostics.
    --  Global microbiome market, global breakdown, application breakdown and
        leading market players
    --  Detailed account of the microbiome industry market by geography,
        indication and company profiles
    --  Profiles, pipeline products, financial analysis and business strategy of
        the major companies in this space
    --  Focus on current trends, business environment, pipeline products,
        clinical trials, and future market forecast for microbiome therapeutics
        and diagnostics
    --  Insight into the challenges faced by stakeholders
    --  Insight into the biobanking industry globally and its impact on the
        overall market
    --  Description and data for the prevalence of disease types that are
        addressed by harnessing the human microbiota
    --  Financial market forecast through 2023 with CAGR values of all market
        segments outlined in the objective
    --  SWOT analysis of the global market
    --  Geographical analysis and challenges within key topographies including
        North America, Europe, Asia/Pacific, Middle East/Africa, ROW

Key Questions Answered:

    --  What are the Main Microbiome Therapeutics in the Pipeline?
    --  What are the Main Microbiome Diagnostics in the Pipeline?
    --  What Key Biologics are in the Pipeline?
    --  How Many Human Therapeutic and Diagnostic Microbiome Products are in the
        Pipeline?
    --  What is the Human Therapeutic Pipeline like by Drug, Company and Stage
        of Development?
    --  What Microbiome Therapeutics are in the Clostridium Difficile Infection
        Pipeline?
    --  Who are the Major Players in the Therapeutic and Diagnostic Spaces?
    --  What will the Microbiome Therapeutic Market be Worth in 2023?
    --  What will the Microbiome Therapeutic Sub-Markets (Gastrointestinal,
        Metabolic, Cancer, Neurological, Autoimmune, Skin) be Worth in 2023?
    --  What will the Microbiome Diagnostic Market be Worth in 2023?
    --  What will the Microbiome Diagnostic Sub-Markets (Gastrointestinal,
        Metabolic, Cancer, Neurological, Autoimmune, Skin) be Worth in 2023?
    --  What are the Main Drivers, Threats and Opportunities of these Markets?
    --  What were the Most Influential Market Deals to Date?
    --  How Much Venture Capital has Been Invested in the Microbiome Industry?
    --  What Major Microbiome Companies have Received Investment?
    --  What Microbiota are Associated with Cancer Development?
    --  How does Gut Dysbiosis influence the Host Inflammatory Response?
    --  Is there an Association Between the Development of Diabetes and Our
        Microbiota?
    --  How does Clostridium difficile Infection Impact the Microbiome?
    --  What Host-Microbe Interactions Occur During the Pathogenesis of Dental
        Caries?
    --  During Cirrhosis of the Liver, What Brain Dysfunction Occurs Due to Gut
        Dysbiosis?
    --  What are the Main Therapeutic Intervention Strategies for Microbiome
        Dysbiosis
    --  What Safety Requirements are Needed for Microbiome Therapeutics?
    --  What Clinical Trials are Investigating Probiotics and Obesity?
    --  What Clinical Trials are Investigating Probiotics and Type 2 Diabetes
        and Non-Alcoholic Fatty Liver Disease?
    --  What Clinical Trials are Investigating Probiotics and Irritable Bowel
        Syndrome?
    --  What Clinical Trials are Investigating Probiotics and Obesity?
    --  How Has the Human Microbiome Project Investigated IBD, Prediabetes and
        Pregnancy?

Key Topics Covered:

Chapter 1 Executive Summary
1.1 Synopsis
1.2 Objective of Report
1.3 Executive Summary
1.4 Key Questions Answered
1.5 Data Sources & Methodology

Chapter 2 Microbiome Overview
2.1 Microbiome Overview
2.2 Human Microbiome in Health and Disease
2.2.1 Cancer
2.2.2 Obesity
2.2.3 Microbiota Metabolism
2.2.3 Type 2 Diabetes Mellitus
2.2.4 Ulcerative Colitis and Crohn's Disease
2.2.5 Clostridium Difficile Infection
2.2.6 Lactose Intolerance
2.2.7 CNS Disorders (gut brain axis)
2.2.8 Dental caries
2.2.9 Recurrent Bacterial Vaginosis and Urinary Tract Infection
2.2.10 Skin Diseases
2.2.11 Hyperoxaluria
2.2.12 Urea Cycle Disorder
2.2.13 Celiac Disease
2.2.14 Non-alcoholic Steatohepatitis (NASH)
2.2.15 Hepatic Encephalopathy
2.3 Types of Microbiome therapeutics
2.3.1 Prebiotics
2.3.2 Live BioTherapeutic Agents (Probiotics)
2.3.3 Fecal Microbiota Transplantation (FMT)
2.3.4 Small Molecules
2.4 Advances in Microbiome Research
2.4.1 MetaHIT Consortium
2.4.2 Human Microbiome Project
2.4.3 Functional Metagenomics
2.4.4 Microbiome Metabolomics
2.4.5 Identifying Microbiome Targets - Enterome EB8018 Case Study
2.5 Geographical Variation of Microbiome Composition

Chapter 3 Human Therapeutic and Diagnostic Pipeline Analysis
3.0 Synopsis
3.1 Clostridium Difficile
3.1.1 SER-109 Seres Therapeutics
3.1.2 SER-262 Seres Therapeutics
3.1.3 RBX2660 Rebiotix
3.1.4 VE303 Vedanta Biosciences
3.1.5 IMM-529 Immuron
3.1.6 MET-2 NuBiyota
3.1.7 CP101 Finch Therapeutics
3.1.8 ABI-M101 Assembly Biosciences
3.1.9 CBM-588 Osel
3.1.10 SYN-004 Synthetic Biologics
3.1.11 SYN-006 Synthetic Biologics
3.2 Ulcerative Colitis
3.2.1 FIN-524 Finch Therapeutics
3.2.2 SER-287 Seres Therapeutics
3.2.3 ABI-M201 Assembly Biosciences
3.3 Crohn's Disease
3.3.1 ABI-M301 Assembly Biosciences
3.3.2 Thetanix 4D Pharma
3.4 Inflammatory Bowel Disease
3.4.1 SER-301 Seres Therapeutics
3.4.2 SGM-1019 Second Genome
3.4.3 Blautix 4D Pharma
3.4.4 SG-2-0776 Second Genome
3.4.5 IBD110 - Enterome/AbbVie
3.5 Immuno-Oncology
3.5.1 SER-401 Seres Therapeutics
3.5.2 Colon Polyp & Colon Cancer Test - Metabiomics
3.5.3 Colorectal Cancer (CRC) Test - Origin Sciences
3.6 Graft Versus Host Disease
3.6.1 SER-155 Seres Therapeutics
3.7 Urinary Tract Infections
3.7.1 LACTIN-V Osel
3.8 Liver Disease
3.8.1 SGM-1019 Second Genome
3.9 Phenylketoneuria
3.9.1 SYNB1020 Synlogic
3.9.2 SYNB1618 Synlogic

Chapter 4 Market Analysis & Forecast to 2023
4.0 Synopsis
4.1 Market Applications
4.1.1 Clostridium Difficile Infection
4.1.2 Inflammatory Bowel Disease
4.1.3 Ulcerative Colitis
4.1.4 Crohn's Disease
4.1.5 Liver Disease
4.1.6 Immuno-Oncology
4.1.7 Phenylketonuria
4.2 Competitive Landscape
4.3 Market Forecast to 2023
4.3.1 Synopsis
4.3.2 Primary Research, Clinical Trial and Pipeline Trends and Analysis
4.3.3 Revenue Generation from Global Therapeutic and Diagnostic Microbiome Market 2018-2023
4.3.4 Geographical Breakdown Analysis and Forecast to 2023
4.3.5 Therapeutic and Diagnostic Submarket Breakdown By Indication

Chapter 5 Market Drivers, Trends & SWOT Analysis
5.1 Market Drivers & Trends
5.2 Market Threats & Challenges
5.3 Market Opportunities

Chapter 6 Investment and Market Deals
6.1 Public and Private Funding in the Microbiome Space
6.2 Current Market Deals

Chapter 7 Venture Capital and The Microbiome
7.0 Synopsis
7.1 How Much Investment Has been Poured into the Microbiome Space in Recent Years?
7.2 What Investment Firms are Interested in the Microbiome Space?
7.3 What Companies are Receiving Funding?
7.4 What Funding Cycles are Emerging in this Space?

Chapter 8 Major Players and Company Profiles
8.1 4D Pharma
8.2 Abbvie
8.3 Allergan
8.4 Assembly Biosciences
8.5 Bristol Myers Squibb
8.6 C3J Therapeutics
8.7 Da Volterra
8.8 Enterome
8.9 Finch Therapeutics
8.10 Immuron
8.11 Matrisys Bioscience
8.12 Merck
8.13 Osel
8.14 Pfizer
8.15 Quorum Innovations
8.16 Rebiotix
8.17 Second Genome
8.18 Seres Therapeutics
8.19 Synlogic
8.20 Synthetic Biologics
8.21 Takeda
8.22 Vedanta Biosciences

For more information about this report visit

https://www.researchandmarkets.com/research/bvh2sk/global_microbiome?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-microbiome-therapeutics--diagnostics-market-2018-2023---human-therapeutic-and-diagnostic-pipeline-analysis-300713586.html

SOURCE Research and Markets